Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

29 oct. 2015 07h45 HE | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results

RADNOR, Pa., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
29 oct. 2015 07h30 HE | Source: Marinus Pharmaceuticals, Inc.

Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation

Plans to initiate clinical trial in Status Epilepticus Preclinical Models Demonstrate Robust Efficacy in Benzodiazepine-Resistant Status Epilepticus RADNOR, Pa., Oct. 29, 2015 (GLOBE NEWSWIRE)...
26 oct. 2015 07h30 HE | Source: Marinus Pharmaceuticals, Inc.

Marinus Announces Key Initial Observations From Study in PCDH19 Female Pediatric Epilepsy

RADNOR, Pa., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
09 sept. 2015 07h30 HE | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA for Ganaxolone in Focal Onset Seizures

RADNOR, Pa., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
04 août 2015 07h30 HE | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2015 Financial Results

RADNOR, Pa., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
06 juil. 2015 07h30 HE | Source: Marinus Pharmaceuticals, Inc.

Published Data Support Scientific Basis for Ganaxolone Use in PCDH19 Female Epilepsy

RADNOR, Pa., July 6, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today...
16 juin 2015 07h30 HE | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Present at JMP Securities Life Sciences Conference

RADNOR, Pa., June 16, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today...
18 mai 2015 07h30 HE | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Presents Clinical Data of Ganaxolone in Pediatric Epilepsies at Antiepileptic Drug and Device Trials XIII Conference

RADNOR, Pa., May 18, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric...
11 mai 2015 07h30 HE | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2015 Financial Results

RADNOR, Pa., May 11, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric...
25 mars 2015 07h30 HE | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals' Ganaxolone Receives FDA Orphan Drug Designation in PCDH19 Female Epilepsy

RADNOR, Pa., March 25, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today...

Page précédente